Federal cannabis status in 2026 — Schedule I, the proposed Schedule III rule, SAFE Banking, and DOJ enforcement

US federal cannabis policy in May 2026 is a layered structure built up over 55 years. Cannabis has been Schedule I under the Controlled Substances Act since 1970. The state-medical-program era began in 1996 with California's Proposition 215. The state-adult-use era began in 2012 with Colorado and Washington. Through both transitions the federal Schedule I status has not changed. What has changed is the layer of federal-state accommodation: the Rohrabacher-Farr appropriations rider for medical cannabis, the Cole Memorandum and its rescission, the DEA's 2024 proposed Schedule III rule, and the SAFE Banking Act's repeated near-misses.

This hub maps the federal landscape as of mid-2026. It is built for readers who need to understand what federal law actually says before they make a decision — patients, clinicians, employers, businesses, journalists, policy researchers.

The Controlled Substances Act of 1970 and Schedule I status

The Controlled Substances Act (CSA), enacted in 1970 and codified at 21 USC 801 et seq., is the foundation of federal drug law. The CSA places controlled substances in five schedules (I through V) based on three criteria: potential for abuse, accepted medical use, and safety profile under medical supervision. Schedule I is the most restrictive: the substance has high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision.

Cannabis (referred to in the CSA as "marihuana") was placed on Schedule I in the 1970 enactment. Cannabis-derived compounds — THC and synthetic cannabinoids — have been variously scheduled over the intervening decades. THC is currently Schedule I in plant cannabis and Schedule III in the FDA-approved synthetic THC drug dronabinol. CBD is currently Schedule V in the FDA-approved purified CBD drug epidiolex; non-pharmaceutical CBD derived from hemp containing less than 0.3% THC by dry weight is exempt under the 2018 Agriculture Improvement Act.

The legal consequences of Schedule I status:

• Possession of any quantity of cannabis is a federal misdemeanor under 21 USC 844, punishable by up to one year imprisonment and a minimum $1,000 fine (for a first offense). Federal possession cases are uncommon; most state-quantity cases are handled under state law.
• Distribution of cannabis is a federal felony under 21 USC 841, with penalties scaling by quantity. Sentences for distribution of 1,000 or more kilograms or 1,000 or more plants run from 10 years to life under the statutory framework.
• Cultivation of cannabis is treated as distribution under 21 USC 841 with quantity scaling by plant count.

The CSA prohibitions apply on all federal property (national parks, courthouses, military bases, VA facilities, federal office buildings, post offices), on federal vehicles, in federally regulated transportation (DOT 49 CFR Part 40), on tribal land within the jurisdiction of the federal government, and in foreign-commerce contexts including interstate transport.

The Schedule III proposed rule

On May 21, 2024, the Drug Enforcement Administration published a Notice of Proposed Rulemaking titled "Schedules of Controlled Substances: Rescheduling of Marijuana." The proposed rule would move cannabis from Schedule I to Schedule III. The rule was published after a Department of Health and Human Services recommendation transmitted to the DEA in August 2023 concluding that cannabis has currently accepted medical use under specific criteria adopted by HHS.

As of May 2026, the rescheduling rule remains in proposed status. The DEA convened an administrative law judge hearing process in early 2025. The rule has not been finalized.

What rescheduling would change:

• Internal Revenue Code §280E prohibits businesses trafficking in Schedule I or Schedule II controlled substances from deducting ordinary business expenses for federal income-tax purposes. Schedule III status removes cannabis from §280E's reach and substantially reduces the federal tax burden on state-licensed cannabis businesses.
• Research access under the CSA. Schedule I research requires DEA registration with stringent quotas. Schedule III research is administratively simpler and is consistent with research access for other Schedule III substances like ketamine.
• FDA pathway. Schedule III is consistent with FDA-approved drugs that are controlled substances. The proposed rule does not modify FDA's authority to approve specific cannabis-derived drugs through the established approval pathway.

What rescheduling would not change:

• Criminal provisions of the CSA at 21 USC 841 and 844 apply to Schedule III substances as they do to Schedule I. The penalty schedule is reduced for Schedule III versus Schedule I (penalties scale by schedule), but possession and distribution remain federal offenses for non-pharmacy, non-FDA-approved products.
• State medical cannabis dispensaries are not pharmacies. They do not dispense FDA-approved drugs under the federal prescription framework. They would not by themselves become legal under federal law upon rescheduling.
• Federal drug-free-workplace policy under Executive Order 12564 and the Drug-Free Workplace Act applies to all federally controlled substances. The DoD framework under DODI 1010.04 applies to cannabis use without distinguishing among schedules.
• Security-clearance adjudication under SEAD-4 Guideline H applies to all controlled-substance use without distinguishing among schedules.
• DOT 49 CFR Part 40 prohibits marijuana use by safety-sensitive transportation workers. Schedule III status would not modify the DOT five-drug panel.
• VA prescribing. Schedule III status does not authorize VA clinicians to prescribe or recommend cannabis under state medical programs. The federal-clinician prohibition derives from cannabis's status as a controlled substance generally and the absence of FDA-approved plant cannabis products, not specifically from Schedule I.

Rescheduling is the most significant pending federal cannabis change. It is not legalization. The mmjnow editorial review of the proposed rule and its likely implementation timeline is in the federal employment hub.

The Rohrabacher-Farr / Joyce-Blumenauer appropriations rider

The Rohrabacher-Farr amendment (sometimes Rohrabacher-Blumenauer; in current appropriations as Joyce-Blumenauer for the bill's House and Senate sponsors) is an annual appropriations rider first attached to the FY2015 Department of Justice appropriations bill. The rider prohibits DOJ from expending appropriated funds to prevent states from implementing their own medical cannabis laws.

The Ninth Circuit's 2016 decision in United States v. McIntosh, 833 F.3d 1163, interpreted the rider as a substantive limit on federal prosecution: DOJ cannot prosecute a defendant whose conduct strictly complies with the medical-cannabis law of the state where the conduct occurred. The McIntosh framework has been adopted or favorably cited by several other circuits and has been the operative federal-medical-cannabis-enforcement framework since 2016.

Important limits on Rohrabacher-Farr:

• Annual reauthorization. The rider is attached to the annual appropriations bill. Each fiscal year it must be renewed; it has been renewed in every fiscal year since 2014 but is subject to political reversal.
• Strict-compliance requirement. McIntosh protection requires strict compliance with state medical cannabis law. Defendants whose conduct deviates from state-program requirements (operating outside license terms, transporting interstate, distributing outside the licensed system) do not receive the protection.
• Medical only. The rider applies to medical cannabis programs only. Adult-use programs are not covered. Federal prosecution of state-adult-use-compliant conduct is theoretically available; the actual policy has been non-prosecution by enforcement discretion rather than statutory protection.
• Civil-asset-forfeiture. The rider applies to prosecution. Civil asset forfeiture under separate federal authorities continues to operate, though the practice in state-medical-compliant cases has been substantially reduced.
• Criminal-history consequences. Federal cannabis convictions that predate the rider remain on federal records.

SAFE Banking / SAFER Banking

The Secure and Fair Enforcement Banking Act (SAFE Banking; renamed SAFER Banking in the Senate Banking Committee 2023 markup) addresses the federal-state friction that prevents most state-legal cannabis businesses from accessing federally regulated financial services. Federally chartered banks and credit unions are subject to federal Bank Secrecy Act and money-laundering rules that treat funds derived from Schedule I substance trafficking as proceeds of unlawful activity.

The result has been operational: most state-legal cannabis businesses have operated on a substantially cash basis with limited access to depository accounts, payment processing, and lending. The cash exposure creates personal-safety, accounting, and tax-compliance risks. The financial-services exclusion also limits the industry's access to capital.

SAFE/SAFER Banking creates a federal safe harbor for federally regulated financial institutions to provide services to state-legal cannabis businesses without triggering federal money-laundering exposure. The House has passed SAFE Banking seven times since 2019. The Senate has not enacted any version. As of May 2026 SAFER Banking remains pending in the Senate Banking Committee.

SAFE/SAFER Banking does not legalize cannabis. It does not modify the CSA. It does not modify federal-employment or clearance policy. It modifies federal banking and money-laundering frameworks. Its enactment would substantially modernize the financial infrastructure of state-legal cannabis programs.

The DOJ enforcement memoranda

A series of Department of Justice memoranda have shaped federal cannabis enforcement posture without modifying the CSA itself.

Ogden Memorandum (October 2009). Deputy Attorney General David Ogden directed federal prosecutors not to focus enforcement resources on individuals in clear and unambiguous compliance with state medical-cannabis laws. The Ogden Memo was the first explicit federal accommodation of state medical programs.

Cole Memorandum (August 2013). Deputy Attorney General James Cole extended the Ogden framework to adult-use programs in Colorado and Washington and articulated eight enforcement priorities (preventing distribution to minors; preventing revenue flow to criminal enterprises; preventing diversion to non-legal states; preventing state-authorized activity from being used as a cover for trafficking; preventing violence and firearms use; preventing drugged driving; preventing growing on federal land; preventing possession on federal property). State-licensed conduct consistent with these priorities and operating under "strong and effective regulatory and enforcement systems" was a low priority for federal prosecution.

Cole Memo II (February 2014). A follow-on memo addressing financial institutions' interaction with state-legal cannabis businesses, paired with FinCEN guidance on suspicious-activity-report filing for state-legal cannabis transactions.

Sessions Memorandum (January 2018). Attorney General Jeff Sessions rescinded the Cole Memo and directed prosecutors to apply standard federal enforcement criteria. The Sessions rescission was not followed by a wave of federal prosecution against state-compliant conduct; in practice federal prosecutors continued to deprioritize state-compliant cases under the Sessions framework, but the formal protection was removed.

Garland Era (2021-present). Attorney General Merrick Garland did not reissue the Cole Memo but signaled in confirmation testimony and subsequent statements that federal enforcement priorities for cannabis would continue to focus on the eight Cole-Memo priorities. Practical federal enforcement of state-compliant conduct has been minimal during the Biden administration.

The Federal Cannabis Status Timeline

The timeline below is built into the route component from the historical record and is the canonical chronology of federal cannabis events from 1970 to 2026.

What's pending and what's stalled

The federal cannabis-policy queue as of May 2026 includes:

• Schedule III rescheduling rule. Proposed in May 2024; administrative review pending; finalization not yet announced.
• SAFER Banking. Pending in Senate Banking Committee since 2023 markup.
• Cannabis Administration and Opportunity Act (CAOA). Senate Democratic leadership bill that would deschedule cannabis entirely, expunge federal cannabis convictions, and establish a federal regulatory framework for state-legal cannabis. CAOA has not advanced past introduction in any Congress since first introduction in 2021.
• States Reform Act. House Republican alternative that would deschedule cannabis and leave regulation primarily to states, with limited federal regulatory presence. Has not advanced past introduction.
• Veterans Equal Access Act / Veterans Medical Marijuana Safe Harbor Act. Multiple iterations would authorize VA clinicians to recommend or certify under state medical programs. Has not cleared either chamber as a standalone bill; provisions have been included in some appropriations vehicles without enactment.
• MORE Act. House Democratic alternative that would deschedule, expunge, and establish federal regulatory framework. Passed the House in 2020 and 2022. Not advanced in the Senate.

The pattern is consistent. Major federal cannabis reforms generate substantial House momentum but stall in the Senate. The Schedule III administrative pathway is the closest pending change to enactment as of mid-2026.

What this means for state programs

State medical and adult-use cannabis programs continue to operate under the federal accommodation framework: Rohrabacher-Farr for medical, prosecutorial discretion for adult use. The federal Schedule I status creates persistent friction in banking, taxation under §280E, federal employment and clearance, federally subsidized housing, federal firearms eligibility, and interstate commerce. None of those frictions has been resolved by federal legislation since cannabis was first scheduled in 1970.

Schedule III status, if finalized, would resolve the §280E friction and substantially modernize federal research access. SAFER Banking, if enacted, would resolve the banking friction. The other federal frictions (employment, clearance, housing, firearms, interstate commerce) would require separate federal legislative or regulatory action.

The mmjnow federal employment hub addresses the workforce frictions in detail. The reciprocity hub addresses the interstate-commerce friction. The how to get a medical card hub covers the state-program mechanics that operate alongside this federal landscape.

Frequently asked questions

The five most-common questions about federal cannabis status are answered at the top of this hub (visible in the FAQ schema). For per-state context see the states index; for the federal-employment specifics see the federal employment hub; for related legislation see legislation.